2023年儿童多炎症综合征（MIS-C）：是时候将其抛诸脑后了吗？
Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?
作者信息
La Torre Francesco, Taddio Andrea, Conti Chiara, Cattalini Marco
机构信息
Pediatric Rheumatology Center, Department of Pediatrics, Giovanni XXIII Pediatric Hospital, University of Bari, 70121 Bari, Italy.
Institute of Child and Maternal Health-IRCCS "Burlo Garofolo", University of Trieste, 34127 Trieste, Italy.
出版信息
Children (Basel). 2023 May 31;10(6):980. doi: 10.3390/children10060980.
Abstract
Multisystem inflammatory syndrome in children (MIS-C) is defined as a clinically serious condition requiring hospitalization involving fever, multi-system organ dysfunction, and an increase in inflammatory biomarkers. The syndrome was originally described as a post-infectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which usually causes COVID-19. During the COVID-19 pandemic, not only did the virus undergo mutations but vaccines against SARS-CoV-2 were also developed. Both these conditions led to a decrease in the incidence of MIS-C. This narrative review summarizes the recent updates for MIS-C, particularly regarding the change in incidence, the link between the SARS-CoV-2 vaccine and MIS-C, and new updates of MIS-C treatments.
摘要
儿童多系统炎症综合征（MIS-C）被定义为一种需要住院治疗的临床严重病症，其症状包括发热、多系统器官功能障碍以及炎症生物标志物升高。该综合征最初被描述为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的一种感染后并发症，SARS-CoV-2通常会引发冠状病毒病（COVID-19）。在冠状病毒病大流行期间，不仅病毒发生了变异，针对SARS-CoV-2的疫苗也得以研发。这两种情况都导致了MIS-C发病率的下降。本叙述性综述总结了MIS-C的最新进展，特别是关于发病率的变化、SARS-CoV-2疫苗与MIS-C之间的联系以及MIS-C治疗的新进展。
相似文献
1
Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?
Children (Basel). 2023 May 31;10(6):980. doi: 10.3390/children10060980.
2
The Spectrum of Manifestations of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) Infection in Children: What We Can Learn From Multisystem Inflammatory Syndrome in Children (MIS-C).
Front Med (Lausanne). 2021 Oct 28;8:747190. doi: 10.3389/fmed.2021.747190. eCollection 2021.
3
Four Distinct Cases of Multisystem Inflammatory Syndrome in Adults Associated With SARS-CoV-2 Infection at a Community Hospital in New Jersey.
Cureus. 2021 Dec 23;13(12):e20651. doi: 10.7759/cureus.20651. eCollection 2021 Dec.
4
Multisystem inflammatory syndrome in neonates (MIS-N) associated with SARS-CoV2 infection: a case series.
Eur J Pediatr. 2022 May;181(5):1883-1898. doi: 10.1007/s00431-022-04377-z. Epub 2022 Jan 14.
5
Multisystem Inflammatory Syndrome in Children (MIS-C).
Curr Allergy Asthma Rep. 2022 May;22(5):53-60. doi: 10.1007/s11882-022-01031-4. Epub 2022 Mar 22.
6
Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5-11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022.
J Infect Dis. 2023 Jul 14;228(2):143-148. doi: 10.1093/infdis/jiad051.
7
Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review.
J Pediatr Rehabil Med. 2020;13(3):301-316. doi: 10.3233/PRM-200794.
8
SARS-CoV-2 infection in the context of Kawasaki disease and multisystem inflammatory syndrome in children.
Med Microbiol Immunol. 2023 Feb;212(1):3-12. doi: 10.1007/s00430-022-00756-3. Epub 2022 Nov 17.
9
Human and novel coronavirus infections in children: a review.
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
10
Multisystem Inflammatory Syndrome in an Adolescent Following SARS-CoV-2 Exposure Despite Three Doses of a COVID-19 Vaccine.
R I Med J (2013). 2022 Jun 1;105(5):41-45.
引用本文的文献
1
Genetic Variants Affect Distinct Metabolic Pathways in Pediatric Multisystem Inflammatory Syndrome and Severe COVID-19.
J Med Virol. 2025 Aug;97(8):e70556. doi: 10.1002/jmv.70556.
2
Advancing multidisciplinary management of pediatric hyperinflammatory disorders.
Front Pediatr. 2025 Apr 30;13:1553861. doi: 10.3389/fped.2025.1553861. eCollection 2025.
3
Diagnostic accuracy of visual triage checklist in early recognition of COVID-19 cases in the pediatric population: A retrospective cohort study.
BMC Pediatr. 2025 May 2;25(1):352. doi: 10.1186/s12887-025-05693-7.
4
Proteomic Signatures of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Narrative Review.
Children (Basel). 2024 Sep 26;11(10):1174. doi: 10.3390/children11101174.
5
Clinical and Laboratory Parameters Associated with PICU Admission in Children with Multisystem Inflammatory Syndrome Associated with COVID-19 (MIS-C).
J Pers Med. 2024 Sep 23;14(9):1011. doi: 10.3390/jpm14091011.
6
Asymptomatic SARS-COV2 Infection or COVID-19 vaccination effect for severe multisystem inflammatory syndrome in a 6-year-old girl: case report and review of the literature.
Ital J Pediatr. 2024 Sep 27;50(1):194. doi: 10.1186/s13052-024-01758-y.
7
Complications of Multisystem Inflammatory Syndrome Associated with SARS-CoV-2 Infection-Many Facets of One Disease-A Literature Review Based on a Case Report.
J Clin Med. 2024 Jul 16;13(14):4146. doi: 10.3390/jcm13144146.
8
An epidemiological study of multisystem inflammatory syndrome in children (MIS-C) and young adults among COVID-19-positive patients - data from National Inpatient Sample database.
Reumatologia. 2024;62(3):214-216. doi: 10.5114/reum/189213. Epub 2024 Jun 7.
9
Evolution of Cardiovascular Findings in Multisystem Inflammatory Syndrome in Children (MIS-C) Across COVID-19 Variants: Common Trends and Unusual Presentations.
Pediatr Cardiol. 2024 Mar;45(3):552-559. doi: 10.1007/s00246-023-03397-2. Epub 2024 Jan 23.
10
Short-term and medium-term clinical outcomes of multisystem inflammatory syndrome in children: a prospective observational cohort study.
Ital J Pediatr. 2024 Jan 4;50(1):1. doi: 10.1186/s13052-023-01569-7.
本文引用的文献
1
Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper.
Pediatr Allergy Immunol. 2023 Jan;34(1):e13900. doi: 10.1111/pai.13900.
2
Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report.
Front Pediatr. 2023 Jan 4;10:1015617. doi: 10.3389/fped.2022.1015617. eCollection 2022.
3
Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children.
JAMA Netw Open. 2023 Jan 3;6(1):e2248987. doi: 10.1001/jamanetworkopen.2022.48987.
4
Risk of paediatric multisystem inflammatory syndrome (PIMS-TS) during the SARS-CoV-2 alpha and delta variant waves: National observational and modelling study, 2020-21, England.
Front Pediatr. 2022 Dec 5;10:1034280. doi: 10.3389/fped.2022.1034280. eCollection 2022.
5
Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): An international survey.
Front Pediatr. 2022 Nov 9;10:1030083. doi: 10.3389/fped.2022.1030083. eCollection 2022.
6
Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant.
Lancet Reg Health West Pac. 2022 Oct 7;27:100604. doi: 10.1016/j.lanwpc.2022.100604. eCollection 2022 Oct.
7
Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review.
Vaccines (Basel). 2022 Sep 2;10(9):1454. doi: 10.3390/vaccines10091454.
8
The Impact of SARS-CoV-2 Variants on the Clinical Phenotype and Severity of Multisystem Inflammatory Syndrome in Children in South Africa.
Pediatr Infect Dis J. 2022 Dec 1;41(12):e510-e512. doi: 10.1097/INF.0000000000003691. Epub 2022 Sep 5.
9
A Suspected Case of Multisystem Inflammatory Disease in Children Following COVID-19 Vaccination: A Case Report and Systematic Literature Review.
Pediatr Infect Dis J. 2022 Nov 1;41(11):e456-e460. doi: 10.1097/INF.0000000000003674. Epub 2022 Aug 25.
10
A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children.
Curr Opin Rheumatol. 2023 Jan 1;35(1):6-16. doi: 10.1097/BOR.0000000000000910. Epub 2022 Sep 12.
Zotero 插件